Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Salbutamol
Form:
20 of 20 products shown
7 general benefit · 5 Limited Use · 8 not a benefit
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208229
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Pharmascience inc · schedule Prescription
PMS-Salbutamol: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3617). What the ministry pays, not the patient.
DIN 02208229: PMS-Salbutamol
Raw flags: sec12=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id PMS
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3617; ministry $0.3617
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02208229
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19763Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617
Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended March 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02208229
Shortage record checked October 6, 2026
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · 1 mg/mL · Inh Sol- 2.5mL Pk
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 01926934
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2012-07-06 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 1 MG/ML · company Teva canada limited · schedule Prescription
Teva-Salbutamol Sterinebs P.F.: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3617). What the ministry pays, not the patient.
DIN 01926934: Teva-Salbutamol Sterinebs P.F.
Raw flags: sec12=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id TEV
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3617; ministry $0.3617
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926934
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13550Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617
Ventolin Nebules P.F. · DIN 02213419 · not recorded
Shortage status: resolved shortage (ended November 5, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926934
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Salbutamol · DIN 02208237
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 2010-05-07 · brand PMS-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Pharmascience inc · schedule Prescription
PMS-Salbutamol: Formulary list price $0.68 per unit (the source does not state the unit; exact figure $0.6750). What the ministry pays, not the patient.
DIN 02208237: PMS-Salbutamol
Raw flags: sec12=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id PMS
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6750; ministry $0.6750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02208237
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19762Interchangeable products
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750
Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended November 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02208237
Shortage record checked October 6, 2026
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · 2 mg/mL · Inh Sol- 2.5mL Pk
Limited Use, Reason for Use code 265, 266, 267, 268 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Salbutamol Sterinebs P.F. · DIN 02173360
Manufacturer: Teva Canada Limited; listing date 1997-04-10
Health Canada: Marketed since 2012-07-05 · brand TEVA-SALBUTAMOL STERINEBS P.F. · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG/ML · company Teva canada limited · schedule Prescription
DIN 02173360: Teva-Salbutamol Sterinebs P.F.
Raw flags: sec12=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id TEV
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.6871; ministry $0.6750
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02173360
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19058Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750
Ventolin Nebules P.F. · DIN 02213427 · not recorded
Shortage status: resolved shortage (ended June 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02173360
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Ventolin · DIN 02213486
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-04-03
Health Canada: Marketed since 2002-08-26 · brand VENTOLIN RESPIRATOR SOLUTION · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/ML · company Glaxosmithkline inc · schedule Prescription
DIN 02213486: Ventolin
Raw flags: sec12=Y, sec3=Y
Item: 121200025; group id 234; item number 0414; lccId 00042; manufacturer id GSK
Source form: Inh Sol-10mL Pk; strength: 5mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.1700; ministry $3.1700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213486
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43108
Shortage status: resolved shortage (ended October 30, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213486
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salbutamol HFA · DIN 02245669
Manufacturer: Apotex Inc.; listing date 2003-01-01
Health Canada: Marketed since 2019-12-16 · brand APO-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Apotex inc · schedule Prescription
Apo-Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.
DIN 02245669: Apo-Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245669
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69769Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported June 16, 2026, last updated June 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245669
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Salbutamol HFA · DIN 02419858
Manufacturer: Sanis Health Inc.; listing date 2020-04-07
Health Canada: Marketed since 2014-02-13 · brand SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Sanis health inc · schedule Prescription
Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.
DIN 02419858: Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id SAI
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419858
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90447Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended March 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419858
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Salbutamol HFA · DIN 02326450
Manufacturer: Teva Canada Limited; listing date 2011-05-19
Health Canada: Marketed since 2018-03-21 · brand TEVA-SALBUTAMOL HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Teva canada limited · schedule Prescription
Teva-Salbutamol HFA: Formulary list price $5.00 per unit (the source does not state the unit; exact figure $5.0000). What the ministry pays, not the patient.
DIN 02326450: Teva-Salbutamol HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id TEV
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $5.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02326450
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81180Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: resolved shortage (ended March 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02326450
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin HFA · DIN 02241497
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2009-11-13
Health Canada: Marketed since 2001-11-22 · brand VENTOLIN HFA · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
DIN 02241497: Ventolin HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GSK
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $6.0000; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241497
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65137Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Shortage status: resolved shortage (ended April 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241497
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Airomir HFA · DIN 02232570
Manufacturer: Graceway Pharmaceuticals; listing date 1998-12-31
Health Canada: Dormant since 2025-07-30 · brand AIROMIR · ATC R03AC02 SALBUTAMOL · form Aerosol (metered-dose) · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 100 MCG/ACT · company Bausch health, canada inc. · schedule Prescription
DIN 02232570: Airomir HFA
Raw flags: sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GRA
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $6.2593; ministry $5.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02232570
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52048Interchangeable products
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: discontinued (January 4, 2023, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02232570
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 30, 2025 — choose a marketed DIN from the same-category list.
Ventolin · PIN 01961039 · 2 mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Ventolin · DIN 01961039
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 01961039: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id GLA
Source form: Tab; strength: 2mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01961039
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Apo-Salvent · DIN 02146843 · $0.1274
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01961039
Shortage record checked October 6, 2026
Apo-Salvent · DIN 02146843 · 2 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.Discontinued December 20, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-12-20 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Salvent · DIN 02146843
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-12-20 · brand APO-SALVENT TABLETS - 2MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2 MG · company Apotex inc · schedule Prescription
DIN 02146843: Apo-Salvent
Raw flags: sec3=Y
Item: 121200013; group id 235; item number 0416; lccId None; manufacturer id APX
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.1274; ministry $0.1274
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02146843
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18068Interchangeable products
Ventolin · DIN 01961039 · not recorded
Shortage status: discontinued (July 12, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146843
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 20, 2018 — choose a marketed DIN from the same-category list.
Apo-Salvent · DIN 02146851 · 4 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.Discontinued July 12, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-07-12 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Salvent · DIN 02146851
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-07-12 · brand APO-SALVENT TABLETS - 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 4 MG · company Apotex inc · schedule Prescription
DIN 02146851: Apo-Salvent
Raw flags: sec3=Y
Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id APX
Source form: Tab; strength: 4mg
Recorded listing: General benefit
Source prices (unrounded): $0.2134; ministry $0.2134
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02146851
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18067Interchangeable products
Ventolin · DIN 01932691 · not recorded
Shortage status: discontinued (July 12, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146851
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 12, 2018 — choose a marketed DIN from the same-category list.
Ventolin Nebules P.F. · DIN 02213419 · 1 mg/mL · Inh Sol- 2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued July 5, 2022 · checked November 19, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213419
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-10-21
Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 2.5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Ventolin Nebules P.F.: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02213419: Ventolin Nebules P.F.
Raw flags: notABenefit=Y, sec3=Y
Item: 121200048; group id 232; item number 0412; lccId 00040; manufacturer id GSK
Source form: Inh Sol- 2.5mL Pk; strength: 1mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213419
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43100Interchangeable products
PMS-Salbutamol · DIN 02208229 · $0.3617
Teva-Salbutamol Sterinebs P.F. · DIN 01926934 · $0.3617
Shortage status: discontinued (June 17, 2022, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213419
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 5, 2022 — choose a marketed DIN from the same-category list.
Ventolin Nebules P.F. · DIN 02213427 · 2 mg/mL · Inh Sol- 2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.Discontinued July 5, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-07-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin Nebules P.F. · DIN 02213427
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2006-06-15
Health Canada: Cancelled post market since 2022-07-05 · brand VENTOLIN NEBULES P.F. - 5MG/2.5ML · ATC R03AC02 SALBUTAMOL · form Solution · route Inhalation · ingredients SALBUTAMOL (SALBUTAMOL SULFATE) 5 MG/2.5ML · company Glaxosmithkline inc · schedule Prescription
Ventolin Nebules P.F.: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02213427: Ventolin Nebules P.F.
Raw flags: notABenefit=Y, sec3=Y
Item: 121200070; group id 233; item number 0413; lccId 00041; manufacturer id GSK
Source form: Inh Sol- 2.5mL Pk; strength: 2mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213427
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43101Interchangeable products
PMS-Salbutamol · DIN 02208237 · $0.6750
Teva-Salbutamol Sterinebs P.F. · DIN 02173360 · $0.6750
Shortage status: discontinued (June 29, 2022, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213427
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 5, 2022 — choose a marketed DIN from the same-category list.
Ventolin · DIN 01932691 · 4 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued September 10, 1996 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Ventolin · DIN 01932691
Manufacturer: Glaxo Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1996-09-10 · brand VENTOLIN TAB 4MG · ATC R03CC02 SALBUTAMOL · form Tablet · route Oral · ingredients SALBUTAMOL SULFATE 4 MG/TAB · company Glaxo canada inc · schedule Prescription
DIN 01932691: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200021; group id 235; item number 0417; lccId None; manufacturer id GLA
Source form: Tab; strength: 4mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01932691
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15121Interchangeable products
Apo-Salvent · DIN 02146851 · $0.2134
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01932691
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 10, 1996 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued April 17, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Salvent · DIN 00790419
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-04-17 · brand APO-SALVENT AEM 100MCG · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Apotex inc · schedule Prescription
Apo-Salvent: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00790419: Apo-Salvent
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id APX
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00790419
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9941Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: active shortage (reported March 10, 2017, last updated October 5, 2017) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00790419
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 17, 2025 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.Discontinued August 10, 2005 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-08-10 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Novo-Salmol · DIN 00874086
Manufacturer: Novopharm Ltd.; listing date 1996-10-01
Health Canada: Cancelled post market since 2005-08-10 · brand NOVO-SALMOL INHALER 100MCG/AEM · ATC R03CC02 SALBUTAMOL · form Metered-dose aerosol · route Oral · ingredients SALBUTAMOL 100 MCG/ACT · company Novopharm limited · schedule Prescription
Novo-Salmol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00874086: Novo-Salmol
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id NOP
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00874086
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11290Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00874086
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 10, 2005 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.Discontinued July 17, 2009 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-07-17 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ratio-Salbutamol Inhaler · DIN 00851841
Manufacturer: Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2009-07-17 · brand RATIO-SALBUTAMOL · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Ratiopharm inc division of teva canada limited · schedule Prescription
Ratio-Salbutamol Inhaler: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 00851841: Ratio-Salbutamol Inhaler
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id RPH
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00851841
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10209Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin · DIN 02213478 · not recorded
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851841
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 17, 2009 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2003 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-01-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ventolin · DIN 02213478
Manufacturer: Glaxo Wellcome Inc.; listing date 1997-07-12
Health Canada: Cancelled post market since 2003-01-22 · brand VENTOLIN INHALER · ATC R03AC02 SALBUTAMOL · form Metered-dose aerosol · route Inhalation · ingredients SALBUTAMOL 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
DIN 02213478: Ventolin
Raw flags: notABenefit=Y, sec3=Y
Item: 121200012; group id 235; item number 0415; lccId None; manufacturer id GLW
Source form: Inh-200 dose Pk; strength: 100mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213478
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43105Interchangeable products
Airomir HFA · DIN 02232570 · $5.0000
Apo-Salbutamol HFA · DIN 02245669 · $5.0000
Apo-Salvent · DIN 00790419 · not recorded
Novo-Salmol · DIN 00874086 · not recorded
Ratio-Salbutamol Inhaler · DIN 00851841 · not recorded
Salbutamol HFA · DIN 02419858 · $5.0000
Teva-Salbutamol HFA · DIN 02326450 · $5.0000
Ventolin HFA · DIN 02241497 · $5.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213478
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2003 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (R03AC, R03C): coverage varies; not interchangeable
Terbutaline (Bricanyl Turbuhaler): general benefit
Formoterol (Foradil): limited Use 132
Formoterol (Oxeze Turbuhaler): limited Use 132
Indacaterol (Onbrez Breezhaler): limited Use 443
Salmeterol (SereVent Diskus): limited Use 132, 391
Orciprenaline (Alupent): general benefit, not a benefit
10 more in the class list below
Ipratropium bromide/salbutamol
2 Limited Use · 1 not a benefit
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394
Manufacturer: MDA Inc.; listing date 2019-12-20
Health Canada: Marketed since 2026-08-28 · brand IPRATROPIUM BROMIDE AND SALBUTAMOL SULPHATE INHALATION SOLUTION · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Juno pharma canada inc. · schedule Prescription
Ipratropium Bromide and Salbutamol Sulph: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.
DIN 02483394: Ipratropium Bromide and Salbutamol Sulph
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id MDI
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483394
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97384Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: resolved shortage (ended April 16, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483394
Shortage record checked October 6, 2026
Teva-Combo Sterinebs · DIN 02272695 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Teva-Combo Sterinebs · DIN 02272695
Manufacturer: Teva Canada Limited; listing date 2006-01-24
Health Canada: Marketed since 2012-07-17 · brand TEVA-COMBO STERINEBS · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE, R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Teva canada limited · schedule Prescription
Teva-Combo Sterinebs: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8066). What the ministry pays, not the patient.
DIN 02272695: Teva-Combo Sterinebs
Raw flags: sec12=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id TEV
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8066; ministry $0.8066
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272695
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75820Interchangeable products
Combivent UDV · DIN 02231675 · not recorded
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Shortage status: resolved shortage (ended April 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272695
Shortage record checked October 6, 2026
Combivent UDV · DIN 02231675 · 500 mcg/2.5 mg/2.5 mL · Inh Sol-2.5mL Amp Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.Discontinued January 8, 2020 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-01-08 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Combivent UDV · DIN 02231675
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 1998-12-31
Health Canada: Cancelled post market since 2020-01-08 · brand COMBIVENT UDV · ATC R03AL02 SALBUTAMOL AND IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5 MG/2.5ML, SALBUTAMOL (SALBUTAMOL SULFATE) 2.5 MG/2.5ML · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Combivent UDV: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
DIN 02231675: Combivent UDV
Raw flags: notABenefit=Y, sec3=Y
Item: 120800050; group id 208; item number 0378; lccId 00029; manufacturer id BOE
Source form: Inh Sol-2.5mL Amp Pk; strength: 500mcg/2.5mg/2.5mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231675
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51050Interchangeable products
Ipratropium Bromide and Salbutamol Sulph · DIN 02483394 · $0.8066
Teva-Combo Sterinebs · DIN 02272695 · $0.8066
Shortage status: discontinued (January 8, 2020, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231675
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 8, 2020 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (R03AC, R03C): coverage varies; not interchangeable
Terbutaline (Bricanyl Turbuhaler): general benefit
Formoterol (Foradil): limited Use 132
Formoterol (Oxeze Turbuhaler): limited Use 132
Indacaterol (Onbrez Breezhaler): limited Use 443
Salmeterol (SereVent Diskus): limited Use 132, 391
Orciprenaline (Alupent): general benefit, not a benefit
10 more in the class list below
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM
Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL
12:08 Parasympatholytic (Cholinergic Blocking) Agents
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08
and 5 more
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE
Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE
12:12 Sympathomimetic (Adrenergic) Agents
INDICATIONS AND CLINICAL USE
TEVA-SALBUTAMOL STERINEBSTM P.F. (salbutamol sulphate Solution) is indicated for:
• the treatment of severe bronchospasm associated with exacerbations of chronic bronchitis
and bronchial asthma. It can be used by “wet” nebulization. When administered through a
nebulizer, it should be used with compressed air or oxygen.
Pediatrics (< 5 years of age):
Experience is insufficient for recommending the treatment of children under 5 years of age.
https://pdf.hres.ca/dpd_pm/00084629.PDF
PM date: October 28, 2022
Source product: TEVA-SALBUTAMOL STERINEBS P.F.; DIN 01926934; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide) Inhalation
Solution in unit dose vials is indicated for the management of bronchospasm in
patients suffering from chronic obstructive pulmonary disease (COPD) who require
regular treatment with both ipratropium and salbutamol.
Treatment should be initiated and administered under medical supervision, e.g.
in the hospital setting. Home based treatment can be recommended in exceptional
cases (severe symptoms or experienced patients requiring higher doses) when a
low dose rapid acting beta-agonist bronchodilator has been insufficient in
providing relief after consultation with an experienced physician.
Administration should be stopped when sufficient symptom relief is achieved.
Pediatrics:
The efficacy and safety in children and adolescents under 18 years has not been
established. TEVA-COMBO Sterinebs® (salbutamol sulphate and ipratropium bromide)
Inhalation Solution is not indicated in this patient population.
Geriatrics:
Page 3 of 48
Elderly patients can use TEVA-COMBO Sterinebs® (s…
https://pdf.hres.ca/dpd_pm/00033894.PDF
PM date: March 1, 2016
Source product: TEVA-COMBO STERINEBS; DIN 02272695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Salbutamol HFA · DIN 02245669
Shortage status: active shortage (reported 2026-06-16, last updated 2026-06-18); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245669
Apo-Salvent · DIN 02146843
Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146843
Apo-Salvent · DIN 02146851
Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146851
Ventolin Nebules P.F. · DIN 02213419
Shortage status: discontinued (2022-06-17, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213419
Ventolin Nebules P.F. · DIN 02213427
Shortage status: discontinued (2022-06-29, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02213427
Apo-Salvent · DIN 00790419
Shortage status: active shortage (reported 2017-03-10, last updated 2017-10-05) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00790419
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)
Other review policies
For Ventolin, Ventolin Nebules P.F., Apo-Salvent, Novo-Salmol, Ratio-Salbutamol Inhaler, Combivent UDV: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.